Shares in rare disease specialist Sarepta Therapeutics (Nasdaq: SRPT) fell around 45% after hours on Thursday, following mixed results from a Phase II study in Duchenne muscular dystrophy (DMD).
The firm announced top-line results from Part 1 of Study 102, a trial testing the safety, efficacy and tolerability of a single dose of gene transfer therapy candidate SRP-9001.
The therapy is intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze